Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback